Chemomab Therapeutics (CMMB) Net Income (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Net Income came in at $625.7 billion in Q4 2025, up 65.9% YoY from $377.1 billion in Q4 2024, and up 35917280.2% on a QoQ basis from $1.7 million in Q3 2025.
Chemomab Therapeutics (CMMB) Net Income (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Net Income data on file, last reported at $625.7 billion in Q4 2025.
- Quarterly Net Income rose 65.9% year-over-year to $625.7 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $625.7 billion (up 65.9% YoY) and the FY2025 annual result came in at -$9.0 million, up 35.5% from the prior year.
- Net Income grew to $625.7 billion in Q4 2025, from $1.7 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $625.7 billion in Q4 2025 to a low of -$37.5 million in Q3 2023.
- A 5-year average of $55.7 billion and a median of $3.4 million in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income tumbled 933.29% — and 2024, when it jumped 11036839.42%.
- Tracing CMMB's Net Income over 5 years: stood at -$5.0 million in 2021, then surged by 263.86% to $8.3 million in 2022, then plunged by 58.59% to $3.4 million in 2023, then jumped by 11036839.42% to $377.1 billion in 2024, then soared by 65.9% to $625.7 billion in 2025.
- The last three Net Income figures came in at $625.7 billion (Q4 2025), $1.7 million (Q3 2025), and $377.1 billion (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | 625.68 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 625.68 Bn |
| Sep 30, 2025 | 1.74 Mn |
| Dec 31, 2024 | 377.13 Bn |
| Sep 30, 2024 | 3.48 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | -37.53 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 8.71 Mn |
| Dec 31, 2022 | 8.25 Mn |
| Sep 30, 2022 | -30.67 Mn |
| Jun 30, 2022 | 7.28 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | -5.04 Mn |
| Sep 30, 2021 | -2.97 Mn |
| Jun 30, 2021 | -2.77 Mn |
| Mar 31, 2021 | -1.70 Mn |
| Dec 31, 2020 | -6.38 Mn |
| Sep 30, 2020 | -2.45 Mn |